Exploratory research for biomarkers relevant to the diagnosis and metastatic risk assessment of pheochromocytoma and paraganglioma

Exploratory research for biomarkers relevant to the diagnosis and metastatic risk assessment of pheochromocytoma and paraganglioma - Exploratory research for biomarkers relevant to the diagnosis and metastatic risk assessment of pheochromocytoma and paraganglioma

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054870

Enrollment

180

Registered

2024-07-03

Start date

2024-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pheochromocytoma and paraganglioma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with pheochromocytoma/paraganglioma (PPGL) 2) Carriers of pathological variants who are genetically at high risk of developing PPGL (PPGL-naive patients) 3) Patients with other adrenal tumours (e.g. adrenal adenoma, adrenocortical carcinoma, neuroblastoma) as a control group and healthy subjects.

Exclusion criteria

Exclusion criteria: 1) Patients on treatment for active malignancies other than PPGL (but not excluding patients with hereditary syndromes coexisting with PPGL such as multiple endocrine neoplasia or von Hippel-Lindau disease) 2) Patients deemed inappropriate for inclusion in the study by the Principal Investigator/contributor

Design outcomes

Primary

Measure	Time frame
Correlation between blood and urine metabolites and clinical stage	—

Countries

Japan

Contacts

Public ContactMASATO YONAMINE

Faculty of Medicine, University of Tsukuba, Ibaraki, Japan Laboratory of Laboratory/Sports Medicine,

yonamine.masato.fu@un.tsukuba.ac.jp0298533209

Outcome results